/ALSE
ALSE Stock - Alseres Pharmaceuticals, Inc.
Healthcare|BiotechnologyOTC
$0.01+100.00%
+$0.01 (+100.00%) • Jul 23
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALSE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$0.01
STOP LOSS$0.01
RISK/REWARD1:NaN
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.21
52W High$0.01
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|
| Revenue | $473,730 | $530,720 | N/A | N/A | N/A |
| Gross Profit | $450,043 | $530,720 | N/A | N/A | N/A |
| Gross Margin | 95.0% | 100.0% | N/A | N/A | N/A |
| Operating Income | $-970,000 | $-1,212,000 | $-1,565,000 | $-3,123,000 | $-8,326,000 |
| Net Income | $-942,000 | $-1,645,000 | $-2,882,000 | $512,419 | $-10,777,000 |
| Net Margin | -198.8% | -310.0% | N/A | N/A | N/A |
| EPS | $-153.67 | $-268.56 | $-486.45 | $50.00 | $-2306.71 |
Company Overview
Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ALSEBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-50.00
Q3 2014
EPS Surprise History
Q3 12
No data
Q4 12
No data
Q2 13
No data
Q3 13
No data
Q4 13
No data
Q4 13
No data
Q2 14
No data
Q3 14
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2014 | Aug 14, 2014 | — | $-50.00 | — | — |
Q2 2014 | May 23, 2014 | — | $-50.00 | — | — |
Q4 2013 | Dec 31, 2013 | — | $39.02 | — | — |
Q4 2013 | Nov 14, 2013 | — | $-50.00 | — | — |
Q3 2013 | Aug 9, 2013 | — | $-100.00 | — | — |
Q2 2013 | May 17, 2013 | — | $-100.00 | — | — |
Q4 2012 | Dec 31, 2012 | — | $-74.93 | — | — |
Q3 2012 | Sep 30, 2012 | — | $-93.38 | — | — |
Q2 2012 | Jun 30, 2012 | — | $-48.13 | — | — |
Q1 2012 | Mar 31, 2012 | — | $-52.11 | — | — |
Q4 2011 | Dec 31, 2011 | — | $-125.41 | — | — |
Q3 2011 | Sep 30, 2011 | — | $-75.29 | — | — |
Q2 2011 | Jun 30, 2011 | — | $-94.26 | — | — |
Q1 2011 | Mar 31, 2011 | — | $-200.97 | — | — |
Q4 2010 | Dec 31, 2010 | — | $-128.03 | — | — |
Q3 2010 | Sep 30, 2010 | — | $756.24 | — | — |
Q2 2010 | Jun 30, 2010 | — | $-303.79 | — | — |
Q1 2010 | Mar 31, 2010 | — | $-363.50 | — | — |
Q4 2009 | Dec 31, 2009 | — | $-356.26 | — | — |
Q3 2009 | Sep 30, 2009 | — | $-442.03 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ALSE
What is ALSE's current stock price?
Alseres Pharmaceuticals, Inc. (ALSE) is currently trading at $0.01 per share. The stock has moved +100.00% today.
What is the analyst price target for ALSE?
No analyst price targets are currently available for this stock.
What sector is Alseres Pharmaceuticals, Inc. in?
Alseres Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ALSE's market cap?
Alseres Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ALSE pay dividends?
No, Alseres Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHKF
Achiko AG
$0.00
Mkt Cap: $0.0B
AGFAF
Digicann Ventures Inc.
$0.02
Mkt Cap: $0.0B
AQQRF
Aquarius Surgical Technologies Inc.
$0.00
Mkt Cap: $0.0B
ELVAY
Evolva Holding S.A.
$1.16
Mkt Cap: $0.0B
FLURF
FluroTech Ltd.
$0.00
Mkt Cap: $0.0B
HOPHF
Hemogenyx Pharmaceuticals Plc
$2.33
Mkt Cap: $0.0B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
KRBP
Kiromic BioPharma, Inc.
$0.08
Mkt Cap: $0.0B
LTTSF
Lotus Ventures Inc.
$0.01
Mkt Cap: $0.0B
PLSI
Phoenix Life Sciences International Limited
$0.00
Mkt Cap: $0.0B
Explore stocks similar to ALSE for comparison